[en] Acquisition of invasive metastatic potential through protease expression is a key event in tumor progression. In carcinomas, the production of metalloproteinases and serine proteinases is regulated by a cross talk between stromal cells and cancer cells. Paradoxically, high rather than low levels of their inhibitors predict poor survival of patients suffering from a variety of cancers. Recent observations suggest a much more complex role of these inhibitors in tumor progression than expected initially.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Noël, Agnès ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme
Albert, V.
Bajou, Khalid ; Université de Liège - ULiège > Département des sciences de la vie > Biologie et génétique moléculaire
Bisson, C.
Devy, L.
Frankenne, Francis
Maquoi, Erik ; Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
Masson, Véronique ; Centre Hospitalier Universitaire de Liège - CHU > Gynécologie-Obstétrique CHR
Sounni, Nor Eddine ; Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
Foidart, Jean-Michel ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique
Language :
English
Title :
New Functions of Stromal Proteases and Their Inhibitors in Tumor Progression
Ahonen M. Baker A.H. Kahari V.M. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells Cancer Res 58 1998 2310 2315
Andreasen P.A. Kjoller L. Christensen L. The urokinase-type plasminogen activator system in cancer metastasis: A review Int J Cancer 72 1997 1 22
Atkinson S.J. Crabbe T. Cowell S. Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes J Biol Chem 270 1995 30479 30485
Atula S. Grenman R. Syrjanen S. Fibroblasts can modulate the phenotype of malignant epithelial cells in vitro Exp Cell Res 235 1997 180 187
Bacharach E. Itin A. Keshet E. Apposition-dependent induction of plasminogen activator inhibitor type 1 expression: A mechanism for balancing pericellular proteolysis during angiogenesis Blood 92 1998 939 945
Bajou K. Noel A. Gerard R.D. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization Nat Med 4 1998 923 928
Baker A.H. George S.J. Zaltsman A.B. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3 Br J Cancer 79 1999 1347 1355
Baramova E.N. Bajou K. Remacle A. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation FEBS Lett 405 1997 157 162
Basbaum C.B. Werb Z. Focalized proteolysis: Spatial and temporal regulation of extracellular matrix degradation at the cell surface Curr Opin Cell Biol 8 1996 731 738
Basset P. Bellocq J.P. Wolf C. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas Nature 348 1990 699 704
Blasi F. The urokinase receptor. A cell surface, regulated chemokine APMIS 107 1999 96 101
Bode W. Fernandez-Catalan C. Tschesche H. Structural properties of matrix metalloproteinases Cell Mol Life Sci 55 1999 639 652
Brooks P.C. Stromblad S. Sanders L.C. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3 Cell 85 1996 683 693
Bugge T.H. Lund L.R. Kombrinck K.K. Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice Oncogene 16 1998 3097 3104
Butler G.S. Butler M.J. Atkinson S.J. The TIMP2 membrane type 1 metalloproteinase “receptor” regulates the concentration and efficient activation of progelatinase A. A kinetic study J Biol Chem 273 1998 871 880
Camps J.L. Chang S.M. Hsu T.C. Fibroblast-mediated acceleration of human epithelial tumor growth in vivo Proc Natl Acad Sci USA 87 1990 75 79
Carmeliet P. Collen D. Development and disease in proteinase-deficient mice: Role of the plasminogen, matrix metalloproteinase and coagulation system Thromb Res 91 1998 255 285
Carmeliet P. Moons L. Lijnen R. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation Nat Genet 17 1997 439 444
Chambers A.F. Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis J Natl Cancer Inst 89 1997 1260 1270
Chapman H.A. Wei Y. Simon D.I. Role of urokinase receptor and caveolin in regulation of integrin signaling Thromb Haemost 82 1999 291 297
Chenard M.P. Lutz Y. Mechine-Neuville A. Presence of high levels of MT1-MMP protein in fibroblastic cells of human invasive carcinomas Int J Cancer 82 1999 208 212
Conese M. Blasi F. Urokinase/urokinase receptor system: Internalization/degradation of urokinase-serpin complexes: Mechanism and regulation Biol Chem Hoppe Seyler 376 1995 143 155
Coucke P. De Leval L. Leyh P. Influence of laminin or fibroblasts upon colony formation in the mouse by B16 melanoma cell spheroids: A morphometric analysis In Vivo 6 1992 119 124
d’Ortho M.P. Will H. Atkinson S. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases Eur J Biochem 250 1997 751 757
Dano K. Romer J. Nielsen B.S. Cancer invasion and tissue remodeling—cooperation of protease systems and cell types APMIS 107 1999 120 127
Dano K. Behrendt N. Brunner N. The urokinase receptor. Protein structure and role of plasminogen activation and cancer invasion Fibrinolysis. 8 1994 189 203
Declerck Y.A. Imren S. Montgomery A.M. Proteases and protease inhibitors in tumor progression Adv Exp Med Biol 425 1997 89 97
Deng G. Curriden S.A. Wang S. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 134 1996 1563 1571
Deryugina E.I. Bourdon M.A. Jungwirth K. Functional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase Int J Cancer 86 2000 15 23
Dvorak H.F. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing N Engl J Med 315 1986 1650 1659
Edwards D.R. Beaudry P.P. Laing T.D. The roles of tissue inhibitors of metalloproteinases in tissue remodelling and cell growth Int J Obes Relat Metab Disord 20 1996 S9 15 Suppl 3
Eitzman D.T. Krauss J.C. Shen T. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma Blood 87 1996 4718 4722
Emonard H.P. Remacle A.G. Noel A.C. Tumor cell surface-associated binding site for the M(r) 72,000 type IV collagenase Cancer Res 52 1992 5845 5848
Gomez D.E. Alonso D.F. Yoshiji H. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions Eur J Cell Biol 74 1997 111 122
Grignon D.J. Sakr W. Toth M. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer Cancer Res 56 1996 1654 1659
Grondahl-Hansen J. Ralfkiaer E. Kirkeby L.T. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans Am J Pathol 138 1991 111 117
Guedez L. Lim M.S. Stetler-Stevenson W.G. The role of metalloproteinases and their inhibitors in hematological disorders Crit Rev Oncog 7 1996 205 225
Guedez L. Stetler-Stevenson W.G. Wolff L. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1 J Clin Invest 102 1998 2002 2010
Guo H. Li R. Zucker S. EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface Cancer Res 60 2000 888 891
Henriet P. Blavier L. Declerck Y.A. Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation APMIS 107 1999 111 119
Himelstein B.P. Canete-Soler R. Bernhard E.J. Induction of fibroblast 92 kDa gelatinase/type IV collagenase expression by direct contact with metastatic tumor cells J Cell Sci 107 1994 477 486
Hiraoka N. Allen E. Apel I.J. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins Cell 95 1998 365 377
Itoh T. Tanioka M. Yoshida H. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice Cancer Res 58 1998 1048 1051
Johnsen M. Lund L.R. Romer J. Cancer invasion and tissue remodeling: Common themes in proteolytic matrix degradation Curr Opin Cell Biol 10 1998 667 671
Kahari V.M. Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion Ann Med 31 1999 34 45
Kayagaki N. Kawasaki A. Ebata T. Metalloproteinase-mediated release of human Fas ligand J Exp Med 182 1995 1777 1783
Khandaker M.H. Mitchell G. Xu L. Metalloproteinases are involved in lipopolysac-charides Blood 93 1999 2173 2185
Khokha R. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1 J Natl Cancer Inst 86 1994 299 304
Koshikawa N. Giannelli G. Cirulli V. Role of cell surface metalloprotease MTI-MMP in epithelial cell migration over laminin-5 J Cell Biol 148 2000 615 624
Koyama H. Raines E.W. Bornfeldt K.E. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors Cell 87 1996 1069 1078
Kruger A. Fata J.E. Khokha R. Altered tumor growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice Blood 90 1997 1993 2000
Kute T.E. Grondahl-Hansen J. Shao S.M. Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence Breast Cancer Res Treat 47 1998 9 16
Llano E. Pendas A.M. Freije J.P. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors Cancer Res 59 1999 2570 2576
Loskutoff D.J. Curriden S.A. Hu G. Regulation of cell adhesion by PAI-1 APMIS 107 1999 54 61
Maquoi E. Frankenne F. Baramova E. Membrane type 1 matrix metalloproteinase-associated degradation of tissue inhibitor of metalloproteinase 2 in human tumor cell lines [In Process Citation] J Biol Chem 275 2000 11368 11378
Martin D.C. Fowlkes J.L. Babic B. Insulin-like growth factor II signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1 J Cell Biol 146 1999 881 892
Masson R. Lefebvre O. Noel A. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy J Cell Biol 140 1998 1535 1541
McCawley L.J. Matrisian L.M. Matrix metalloproteinases: Multifunctional contributors to tumor progression [In Process Citation] Mol Med Today 6 2000 149 156
Montgomery A.M. De Clerck Y.A. Langley K.E. Melanoma-mediated dissolution of extracellular matrix: Contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways Cancer Res 53 1993 693 700
Murphy G. Gavrilovic J. Proteolysis and cell migration: Creating a path? Curr Opin Cell Biol 11 1999 614 621
Murphy G. Stanton H. Cowell S. Mechanisms for pro matrix metalloproteinase activation APMIS 107 1999 38 44
Nielsen B.S. Sehested M. Timshel S. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer Lab Invest 74 1996 168 177
Nishiyama T. Tsunenaga M. Nakayama Y. Growth rate of human fibroblasts is repressed by the culture within reconstituted collagen matrix but not by the culture on the matrix Matrix 9 1989 193 199
Noel A. Bajou K. Masson V. Regulation of cancer invasion and vascularization by plasminogen activator inhibitor-1 Fibrinolysis and Proteolysis 13 2000 220 225
Noel A. Boulay A. Kebers F. Demonstration in vivo that stromelysin-3 functions through its proteolytic activity Oncogene 19 2000 1605 1612
Noel A. Emonard H. Polette M. Role of matrix, fibroblasts, and type IV collagenases in tumor progression and invasion Pathol Res Pract 190 1994 934 941
Noel A. Gilles C. Bajou K. Emerging roles for proteinases in cancer Invasion Metastasis 17 1997 221 239
Noel A. Hajitou A. L’Hoir C. Inhibition of stromal matrix metalloproteases: Effects on breast-tumor promotion by fibroblasts Int J Cancer 76 1998 267 273
Noel A. Pauw-Gillet M.C. Purnell G. Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by matrigel and fibroblasts Br J Cancer 68 1993 909 915
Noel A.C. Lefebvre O. Maquoi E. Stromelysin-3 expression promotes tumor take in nude mice J Clin Invest 97 1996 1924 1930
Noel A.C. Polette M. Lewalle J.M. Coordinate enhancement of gelatinase A mRNA and activity levels in human fibroblasts in response to breast-adenocarcinoma cells Int J Cancer 56 1994 331 336
Pedersen A.N. Brunner N. Hoyer-Hansen G. Determination of the complex between urokinase and its type-1 inhibitor in plasma from healthy donors and breast cancer patients Clin Chem 45 1999 1206 1213
Pepper M.S. Montesano R. Proteolytic balance and capillary morphogenesis Cell Differ Dev 32 1990 319 327
Polette M. Birembaut P. Membrane-type metalloproteinases in tumor invasion Int J Biochem Cell Biol 30 1998 1195 1202
Polette M. Clavel C. Birembaut P. Localization by in situ hybridization of mRNAs encoding stromelysin 3 and tissue inhibitors of metallo-proteinases TIMP-1 and TIMP-2 in human head and neck carcinomas Pathol Res Pract 189 1993 1052 1057
Polette M. Gilles C. Marchand V. Induction of membrane-type matrix metalloproteinase 1 (MT1-MMP) expression in human fibroblasts by breast adenocarcinoma cells Clin Exp Metastasis 15 1997 157 163
Poulsom R. Pignatelli M. Stetler-Stevenson W.G. Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia Am J Pathol 141 1992 389 396
Pyke C. Kristensen P. Ralfkiaer E. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas Am J Pathol 138 1991 1059 1067
Pyke C. Ralfkiaer E. Huhtala P. Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization Cancer Res 52 1992 1336 1341
Remacle A. McCarthy K. Noel A. High levels of TIMP-2 correlate with adverse prognosis in breast cancer Int J Cancer 89 2000 118 121
Reuning U. Magdolen V. Wilhelm O. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review) Int J Oncol 13 1998 893 906
Rifkin D.B. Mazzieri R. Munger J.S. Proteolytic control of growth factor availability APMIS 107 1999 80 85
Rio M.C. Lefebvre O. Santavicca M. Stromelysin-3 in the biology of the normal and neoplastic mammary gland J Mammary Gland Biol Neoplasia 1 1996 231 240
Skobe M. Fusenig N.E. Tumorigenic conversion of immortal human keratinocytes through stromal cell activation Proc Natl Acad Sci USA 95 1998 1050 1055
Smith M.R. Kung H. Durum S.K. TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells Cytokine 9 1997 770 780
Stephens R.W. Nielsen H.J. Christensen I.J. Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis J Natl Cancer Inst 91 1999 869 874
Strongin A.Y. Collier I. Bannikov G. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease J Biol Chem 270 1995 5331 5338
Sugiura Y. Ma L. Sun B. The plasminogen-plasminogen activator (PA) system in neuroblastoma: Role of PA inhibitor-1 in metastasis Cancer Res 59 1999 1327 1336
Thomas G.T. Lewis M.P. Speight P.M. Matrix metalloproteinases and oral cancer Oral Oncol 35 1999 227 233
Tsuojiya H. Katsuo E. Sunayama C. The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice Gen Diag Pathol 141 1995 41 48
Twining S.S. Regulation of proteolytic activity in tissues Crit Rev Biochem Mol Biol 29 1994 315 383
Velasco G. Cal S. Merlos-Suarez A. Human MT6-matrix metalloproteinase: Identification, progelatinase A activation, and expression in brain tumors Cancer Res 60 2000 877 882
Visscher D.W. Hoyhtya M. Ottosen S.K. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence Int J Cancer 59 1994 339 344
von Bredow D.C. Nagle R.B. Bowden G.T. Cleavage of beta 4 integrin by matrilysin Exp Cell Res 236 1997 341 345
Vu T.H. Shipley J.M. Bergers G. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes Cell 93 1998 411 422
Wang M. Liu Y.E. Greene J. Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4 Oncogene 14 1997 2767 2774
Werb Z. ECM and cell surface proteolysis: Regulating cellular ecology Cell 91 1997 439 442
Westermarck J. Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion FASEB J 13 1999 781 792
Will H. Atkinson S.J. Butler G.S. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates auto-proteolytic activation. Regulation by TIMP-2 and TIMP-3 J Biol Chem 271 1996 17119 17123
Wilson C.L. Heppner K.J. Labosky P.A. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin Proc Natl Acad Sci USA 94 1997 1402 1407
Witty J.P. McDonnell S. Newell K.J. Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo Cancer Res 54 1994 4805 4812
Zucker S. Drews M. Conner C. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP) J Biol Chem 273 1998 1216 1222